Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Siltanen S, Syrjäkoski K, Fagerholm R, Ikonen T, Lipman P, Mallott J, Holli K, Tammela TL, Järvinen HJ, Mecklin JP, Aittomäki K, Blomqvist C, Bailey-Wilson JE, Nevanlinna H, Aaltonen LA, Schleutker J, Vahteristo P.

Eur J Hum Genet. 2008 Aug;16(8):983-91. doi: 10.1038/ejhg.2008.43. Epub 2008 Mar 12.

2.

ARLTS1 variants and risk of colorectal cancer.

Frank B, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B.

Cancer Lett. 2006 Dec 8;244(2):172-5. Epub 2006 Feb 20.

PMID:
16488076
3.

Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk.

Frank B, Hemminki K, Meindl A, Wappenschmidt B, Klaes R, Schmutzler RK, Untch M, Bugert P, Bartram CR, Burwinkel B.

Int J Cancer. 2006 May 15;118(10):2505-8.

4.

Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J.

PLoS One. 2011;6(10):e26595. doi: 10.1371/journal.pone.0026595. Epub 2011 Oct 20.

5.

Association of the ARLTS1 variants with familial ovarian cancer risk in China.

Yang XY, Yu H, Xi MR, Yang KX, Pan XL, Hu M, Peng ZL.

Int J Gynecol Cancer. 2009 May;19(4):585-90. doi: 10.1111/IGC.0b013e3181a39d03.

PMID:
19509554
6.

Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer.

Castellví-Bel S, Castells A, de Cid R, Muñoz J, Balaguer F, Gonzalo V, Ruiz-Ponte C, Andreu M, Llor X, Jover R, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Carracedo A, Piqué JM; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Carcinogenesis. 2007 Aug;28(8):1687-91. Epub 2007 Apr 21.

PMID:
17449901
7.

Familial cancer associated with a polymorphism in ARLTS1.

Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM.

N Engl J Med. 2005 Apr 21;352(16):1667-76.

8.

Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene.

Masojć B, Mierzejewski M, Cybulski C, van de Wetering T, Debniak T, Górski B, Jaworowska E, Tarnowska C, Lenner M, Scott RJ, Lubiński J.

Breast Cancer Res Treat. 2006 Sep;99(1):59-62. Epub 2006 Mar 29.

PMID:
16570116
9.

ARLTS1 variants and melanoma risk.

Frank B, Meyer P, Boettger MB, Hemminki K, Stapelmann H, Gast A, Schmitt C, Kumar R, Sergi C, Burwinkel B.

Int J Cancer. 2006 Oct 1;119(7):1736-7.

10.

ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Siltanen S, Fischer D, Rantapero T, Laitinen V, Mpindi JP, Kallioniemi O, Wahlfors T, Schleutker J.

PLoS One. 2013 Aug 5;8(8):e72040. doi: 10.1371/journal.pone.0072040. Print 2013.

11.

Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer.

Jonsson BA, Bergh A, Stattin P, Emmanuelsson M, Grönberg H.

Int J Cancer. 2002 Apr 20;98(6):838-43.

12.

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M, Hamdy FC, Donovan JL, Neal DE, Lane JA, Dearnaley D, Wilkinson RA, Sawyer EJ, Morgan A, Antoniou AC, Eeles RA; UK Genetic Prostate Cancer Study Collaborators, and ProtecT Study Group.

Ann Oncol. 2015 Apr;26(4):756-61. doi: 10.1093/annonc/mdv004. Epub 2015 Jan 16.

PMID:
25595936
13.

Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations.

Yu KD, Di GH, Li WF, Rao NY, Fan L, Yuan WT, Hu Z, Wu J, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2010 May;121(1):157-67. doi: 10.1007/s10549-009-0516-9. Epub 2009 Sep 2.

PMID:
19728081
14.

The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.

Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA.

Cancer Res. 2000 Aug 15;60(16):4513-8. Erratum in: Cancer Res 2000 Dec 15;60(24):7185.

15.

Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer.

Song H, Koessler T, Ahmed S, Ramus SJ, Kjaer SK, Dicioccio RA, Wozniak E, Hogdall E, Whittemore AS, McGuire V, Ponder BA, Turnbull C, Hines S, Rahman N; Breast Cancer Susceptibility Collaboration UK, Eeles RA, Easton DF, Gayther SA, Dunning AM, Pharoah PD.

Cancer Res. 2008 Nov 1;68(21):8837-42. doi: 10.1158/0008-5472.CAN-08-2363.

16.

A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk.

Rokavec M, Justenhoven C, Schroth W, Istrate MA, Haas S, Fischer HP, Vollmert C, Illig T, Hamann U, Ko YD, Glavac D, Brauch H.

Clin Cancer Res. 2007 Dec 15;13(24):7506-14.

17.

ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Jiang Y, Zhao CY, Cheng LC, Xu B, Lv HY.

Hered Cancer Clin Pract. 2017 Jun 13;15:8. doi: 10.1186/s13053-017-0068-7. eCollection 2017. Review.

18.

MGMT Ile143Val polymorphism, dietary factors and the risk of breast, colorectal and prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study.

Loh YH, Mitrou PN, Bowman R, Wood A, Jeffery H, Luben RN, Lentjes MA, Khaw KT, Rodwell SA.

DNA Repair (Amst). 2010 Apr 4;9(4):421-8. doi: 10.1016/j.dnarep.2010.01.002. Epub 2010 Jan 21.

PMID:
20096652
19.

PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).

Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG.

Carcinogenesis. 2010 Mar;31(3):455-61. doi: 10.1093/carcin/bgp307. Epub 2009 Dec 4.

20.

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L, Vessella RL, Auvinen A, Visakorpi T, Tammela TL, Schleutker J.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):452-60. doi: 10.1158/1055-9965.EPI-12-1000-T. Epub 2013 Jan 4.

Supplemental Content

Support Center